In part 2, Christine Pfaff, RPh, MBA, explores reimbursement gaps, new payment models, and payer partnerships needed to expand cellular therapy access. In the second part of her interview at the 2026 ...

Employers need a voice at the table with health systems, hospitals, and carriers in shaping cancer care, according to Rosa ...

Home phototherapy occupies an unusual position in the psoriasis treatment landscape: an option with randomized evidence of ...

Technology, particularly artificial intelligence (AI), represents the biggest structural shift in oncology drug development over the past 5 years, according to David Spigel, MD, p ...

Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill ...

This interview has been lightly edited for clarity.

This commentary discusses the current prior authorization (PA) process and the negative impacts it can have on patient care. According to the American Medical Association, 94% of patients experience ...

Chronic hand eczema commonly reflects overlapping irritant, allergic, atopic, and protein-driven mechanisms, making patch ...

Tampa General Hospital and Moffitt Cancer Center are both racing to expand outpatient capacity, from added observation bays ...

FDA movement of peptides toward 503A bulks listing advanced despite internal scientific objections citing absent human ...

Employers can improve access to cancer care and address rising costs by pairing existing benefits with targeted strategies, ...

The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.